Home › Research › Cognitive tests and assessment
Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays
Blennow K, Shaw LM, Stomrud E, Mattsson N, Toledo JB, Buck K, Wahl S, Eichenlaub U et al.. Scientific reports, 2019-12-13
Topic: Amyloid, tau and blood-test diagnosis
We evaluated the performance of CSF biomarkers for predicting risk of clinical decline and conversion to dementia in non-demented patients with cognitive symptoms. CSF samples from patients in two multicentre longitudinal studies (ADNI, n = 619; BioFINDER, n = 431) were analysed. Aβ(1-42), tTau and pTau CSF concentrations were measured using Elecsys CSF immunoassays, and tTau/Aβ(1-42) and pTau/Aβ(1-42) ratios calculated.
Key findings
- CSF samples from patients in two multicentre longitudinal studies (ADNI, n = 619; BioFINDER, n = 431) were analysed.
- Aβ(1-42), tTau and pTau CSF concentrations were measured using Elecsys CSF immunoassays, and tTau/Aβ(1-42) and pTau/Aβ(1-42) ratios calculated.
- Patients were classified as biomarker (BM)-positive or BM-negative at baseline.
- Ability of biomarkers to predict risk of clinical decline and conversion to AD/dementia was assessed using pre-established cut-offs for Aβ(1-42) and ratios; tTau and pTau cut-offs were determined.
Why it matters
This study measured amyloid-beta 42, total tau and phosphorylated tau in cerebrospinal fluid using Elecsys immunoassays to predict who would decline or develop dementia. It is about predicting risk with biomarkers, not about treating, curing or preventing Alzheimer's disease.
Study details
- Study designlongitudinal study
- Participants619
- Effect sizeHR: 1.67
- Evidence strengthModerate
How this study scored 71/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Scientific reports) |
| Journal's citation record | 3 / 4 | Scientific Reports: journal h-index 463 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 2 / 4 | 619 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 195 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 21.7 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 4 / 6 | Cited 14.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 16 other studies in this library |
| Still being cited | 3 / 4 | Cited 84 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Oskar Hansson: h-index 148 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Pennsylvania: institution h-index 1,859 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 7 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 31836810) |
| Free to read | 2 / 2 | Free to read |
| Total | 71 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1038/s41598-019-54204-z
- PubMed: 31836810
- Original source →
- Free full text: Scientific Reports →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Blennow, K., Shaw, L. M., Stomrud, E., Mattsson, N., Toledo, J. B., Buck, K., et al. (2019). Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays. Scientific reports. https://doi.org/10.1038/s41598-019-54204-z
Vancouver
Blennow K, Shaw LM, Stomrud E, Mattsson N, Toledo JB, Buck K, et al. Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays. Scientific reports. 2019. doi:10.1038/s41598-019-54204-z. PMID: 31836810.
BibTeX
@article{blennow2019-31836810,
author = {Blennow, K. and Shaw, L. M. and Stomrud, E. and Mattsson, N. and Toledo, J. B. and Buck, K. and Wahl, S. and Eichenlaub, U. and others},
title = {{Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays}},
journal = {Scientific reports},
year = {2019},
doi = {10.1038/s41598-019-54204-z},
pmid = {31836810},
url = {https://doi.org/10.1038/s41598-019-54204-z}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 23.
Later studies that cite this one
16 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Cognitive tests and assessment
Also tagged “biomarkers”
821 studies in the library carry the topic tag “biomarkers”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.